Javascript must be enabled to continue!
Frightened Directors
View through CrossRef
The newspapers have published photographs of directors, frightened directors, taken away in handcuffs by broad-shouldered men. These directors are not the subject of this contribution. They have been convicted or are suspected of fraud. It is generally only right and proper that they should be afraid, in view of their social downfall and merited punishment. This contribution is about company directors who act reasonably and yet are in the firing line, or at any rate believe they may be in the firing line. In other words, about directors who are afraid even though they have nothing to fear. If directors are too afraid of liability proceedings and other rules and regulations which attach consequences to their behaviour, side-effects lie in wait. In the case of directors these are manifested in undesirable risk-avoiding behaviour. Directors may shrink from risky but potentially very profitable decisions and choose the safer but less profitable route. This contribution shows that Dutch directors (and directors in other European countries) are indeed afraid. It focuses on the reasons for this fear. The author brings forward some solutions and advocates that liability law has to be applied appropriately in company law and that we must put moral indignation at the behaviour of directors, which is based mainly on certain incidents, behind us. With this contribution, that was given as a speech on 28 October 2005, the author accepted his appointment as Professor of Company Law at Erasmus University Rotterdam, the Netherlands.
Title: Frightened Directors
Description:
The newspapers have published photographs of directors, frightened directors, taken away in handcuffs by broad-shouldered men.
These directors are not the subject of this contribution.
They have been convicted or are suspected of fraud.
It is generally only right and proper that they should be afraid, in view of their social downfall and merited punishment.
This contribution is about company directors who act reasonably and yet are in the firing line, or at any rate believe they may be in the firing line.
In other words, about directors who are afraid even though they have nothing to fear.
If directors are too afraid of liability proceedings and other rules and regulations which attach consequences to their behaviour, side-effects lie in wait.
In the case of directors these are manifested in undesirable risk-avoiding behaviour.
Directors may shrink from risky but potentially very profitable decisions and choose the safer but less profitable route.
This contribution shows that Dutch directors (and directors in other European countries) are indeed afraid.
It focuses on the reasons for this fear.
The author brings forward some solutions and advocates that liability law has to be applied appropriately in company law and that we must put moral indignation at the behaviour of directors, which is based mainly on certain incidents, behind us.
With this contribution, that was given as a speech on 28 October 2005, the author accepted his appointment as Professor of Company Law at Erasmus University Rotterdam, the Netherlands.
Related Results
Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
Abstract
Introduction
The short half-life of standard factor VIII (FVIII) products means that frequent injections (3 to 4 times/week) are needed for e...
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose
Abstract
Background
Myelofibrosis (MF) is a myeloproliferative neoplasm associated with progressive, debilitating symptoms that ...
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Abstract
Background: Imetelstat, a first in class specific telomerase inhibitor, induced hematologic responses in all patients (pts) with essential thrombocythemia (...
Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia
Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia
Introduction: Efforts to safely and effectively treat acute myeloid leukemia (AML) by targeting a single leukemia associated antigen with chimeric antigen receptor T (CAR T) cells ...
Risk of Infections with BCMA-Directed Immunotherapy in Multiple Myeloma
Risk of Infections with BCMA-Directed Immunotherapy in Multiple Myeloma
Abstract
Introduction: B cell maturation antigen (BCMA) is a novel target for T cell immunotherapy in MM including bispecific antibody (bsAb) and chimeric antigen re...
Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial
Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial
Introduction Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody in clinical development for the subcutaneous prophylactic treatment of hemophilia pati...
Plastic Surgery Training and the Problematic Resident
Plastic Surgery Training and the Problematic Resident
Introduction
Plastic surgery resident education is a significant commitment by both programs and residents. Unfortunately, problematic resident behavior may occur and b...
Safety and Efficacy Of Long-Term Open-Label Romiplostim Dosing In Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
Safety and Efficacy Of Long-Term Open-Label Romiplostim Dosing In Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
Abstract
Background
Chronic pediatric ITP is an autoimmune disorder characterized by increased platelet destruction and suboptim...

